Evidence

Equations & derivations

Every equation, constant and reference the calculator uses, so the method can be reviewed and the calculations checked against the cited sources.

Model names, citations and equations on this page use the same reference values as the calculator (calculator version 2026-09-25.1).

1. Population model — Colin 2019

Every adult is dosed with the Colin 2019 two-compartment population PK model. Clearance combines four factors: body size, maturation (effectively 1.0 for adults), age-related decline, and serum creatinine. The equations below show how these factors are multiplied.

Structure:
Two-compartment model, intermittent IV infusion, first-order elimination
Source data:
Pooled population analysis of data from 14 studies (2,554 individuals), from neonates to elderly adults.
Scope in Vancomyzer:
Adults (18 years and older) receiving intermittent IV vancomycin who are not on renal replacement therapy. Used for every body size, including BMI 40 kg/m2 and above.
Kidney-function input:
Serum creatinine is used directly (mg/dL) as the Colin 2019 renal covariate: FSCR = exp(−0.649 × (SCr − SCRstd)), where SCRstd is the age-standardized reference creatinine. Cockcroft-Gault does not enter this population prior; after a fit to measured levels, the calculator caps fitted clearance at twice the estimated CrCl.
CL (L/h) = 5.31 × (WT/70)^0.75 × FMat × FDecline × FSCR
V1 (L) = 42.9 × (WT/70)
V2 (L) = 41.7 × (WT/70)
Q (L/h) = 3.22 × (WT/70)^0.75
PMA (years) = age (years) + 40/52
FMat = PMAwk^2.89 / (PMAwk^2.89 + 46.4^2.89) (≈1 for adults)
FDecline = 1 / (1 + (PMA/61.6)^2.24)
FSCR = exp(−0.649 × (SCr − SCRstd)), SCr in mg/dL
SCRstd = exp(−1.228 + 0.672 × log10(PMA) + 6.27 × exp(−3.11 × PMA))

Typical values (Colin 2019, Table 3):
  θCL   = 5.31 L/h per 70 kg
  θV1   = 42.9 L per 70 kg
  θV2   = 41.7 L per 70 kg
  θQ    = 3.22 L/h per 70 kg
  PMA50 = 46.4 weeks (maturation half-point)
  γ1    = 2.89 (maturation Hill coefficient)
  AGE50 = 61.6 years (PMA at which ageing halves CL)
  γ2    = 2.24 (age-decline Hill coefficient)
  θSCR  = 0.649 per mg/dL

Typical-adult reference check (Age 35 y, weight 70 kg, SCr 0.83 mg/dL):
  CL ≈ 4.10 L/h   V1 = 42.9 L   V2 = 41.7 L   Q = 3.22 L/h

Published patient factors not used

  • Hematological malignancy (+29.4% CL in the published model): not captured as an input.
  • Heel-prick sampling (neonatal): not applicable to adult venous sampling.

Published variability

Between-subject variability (CV): CL 27.9%, V1 27.3%, V2 97.9%; proportional residual error 21.5%. Shown for reference only: the Bayesian fit uses Vancomyzer’s own prior widths (section 7).

Colin PJ, et al. Vancomycin pharmacokinetics throughout life: results from a pooled population analysis and evaluation of current dosing recommendations. Clin Pharmacokinet. 2019;58(6):767-780. doi:10.1007/s40262-018-0727-5

2. Two-compartment rate constants

Vancomycin behaves as a two-compartment drug: a central compartment (V₁) that contains the measured concentration, and a peripheral compartment (V₂) the drug distributes into and slowly returns from. The hybrid rate constants α (fast, distribution) and β (slow, terminal elimination) are the eigenvalues of the system.

k10 = CL / V1
k12 = Q / V1
k21 = Q / V2

α + β = k10 + k12 + k21
α × β = k10 × k21

α = ½ [(k10 + k12 + k21) + √((k10 + k12 + k21)² − 4·k10·k21)]
β = ½ [(k10 + k12 + k21) − √((k10 + k12 + k21)² − 4·k10·k21)]

A = (α − k21) / [V1 × (α − β)]
B = (k21 − β) / [V1 × (α − β)]

Half-lives:
  t½α = ln(2) / α     distribution half-life (~0.5–4h)
  t½β = ln(2) / β     terminal elimination half-life (~6–80h)

3. Single-dose concentration (IV infusion)

Closed-form solution for a constant-rate IV infusion of duration T_inf. During infusion the concentration builds; after the pump stops, it falls as a sum of two exponentials.

R0 = dose_mg / T_inf            (infusion rate, mg/h)

During infusion (0 ≤ t ≤ T_inf):
  C(t) = R0 × [ A/α × (1 − e^(−α·t))
              + B/β × (1 − e^(−β·t)) ]

After infusion (t > T_inf):
  C(t) = R0 × [ A/α × (1 − e^(−α·T_inf)) × e^(−α·(t − T_inf))
              + B/β × (1 − e^(−β·T_inf)) × e^(−β·(t − T_inf)) ]

4. Multi-dose superposition (accumulation to steady state)

For repeated dosing the total concentration at any time is the linear sum of single-dose contributions from every prior dose. The number of doses simulated is chosen so the curve spans at least 5 terminal half-lives (about 97% of steady state).

C_total(t) = Σ C_single(t − k·τ)   for k = 0, 1, 2, …, N−1
             where t ≥ k·τ

Number of doses simulated:
  t½β  = ln(2) / β
  N    = max(10, ceil(5 × t½β / τ) + 2)

This ensures the graph spans enough time for concentrations
to approach steady state.

Levels drawn before steady state, and loading doses

When steady state is not confirmed, a measured level is predicted from exactly the doses given, not from an infinite dose train. When dose 1 was a loading dose, it enters the sum with its own amount and infusion time, and the first maintenance dose starts at the entered gap (default: the dosing interval). Levels are timed from the start of the last dose given.

Dose times (dose 1 = loading dose, N doses given):
  t₁ = 0                         D₁ = loading dose,  T_inf,1 = loading infusion
  t₂ = G                         D  = maintenance,   T_inf   = maintenance infusion
  tⱼ = G + (j − 2)·τ             (G = gap to first maintenance dose; default τ)

Predicted level drawn Δt after dose N started:
  C(t_N + Δt) = Σⱼ C_single(Dⱼ, T_inf,j ; t_N + Δt − tⱼ)

The steady-state projection of the maintenance regimen (section 5)
does not depend on the loading dose.

5. Steady-state AUC₂₄

By linear pharmacokinetics, the steady-state daily exposure depends only on the daily dose and the patient’s clearance — independent of how the dose is split across the day.

AUC₂₄ = (dose_mg / CL) × (24 / τ)

Equivalently:
  AUC₂₄ = TDD / CL    (TDD = total daily dose)

This is exact under linear PK; peak and trough use the
two-compartment steady-state superposition formula
(not the multi-dose simulation) for maximum numerical accuracy.

6. Body size: no model switch

Colin 2019 is used for every adult at every body size, including BMI 40 kg/m² and above. Clearance and volumes scale with total body weight exactly as in section 1: CL and Q with (WT/70)0.75, V1 and V2 with WT/70. There is no BMI threshold at which a different model or different equations are used.

At BMI 40 kg/m² or more, the calculator adds an advisory because published evaluation of this model at that body size is limited. This is the advisory the calculator shows; for a patient weighing 130 kg with a height of 175 cm it reads:

BMI 42.4 kg/m² (40 or more): estimates use the Colin 2019 model with total-body-weight scaling, the same model used for all adults. Published evaluation of this model at BMI 40 or more is limited (Colin 2021: 15 of 49 obese adults), so obtain vancomycin levels early to individualize. Fat-free mass and alternative creatinine-clearance estimates are shown for information only and do not change the calculation.

If height is not entered for a heavier patient, it reads:

Height was not entered, so BMI was not assessed. If BMI is 40 or more, published evaluation of the Colin 2019 model at that body size is limited; obtain vancomycin levels early.

Shown for information only

At BMI 40 kg/m² or more, the calculator also displays fat-free mass and alternative creatinine-clearance estimates so they can be compared with your own assessment. They use the formulas below and do not change the Colin 2019 calculation.

Fat-free mass (Janmahasatian 2005):
  Male:    FFM = (9270 × TBW) / (6680 + 216 × BMI)
  Female:  FFM = (9270 × TBW) / (8780 + 244 × BMI)

Cockcroft-Gault CrCl, on TBW, adjusted body weight or FFM:
  CrCl  = ((140 − age) × weight) / (72 × SCr)   [× 0.85 if female]
  IBW   = 50 kg (male) or 45.5 kg (female) + 2.3 kg per inch over 60 in
  AdjBW = IBW + 0.4 × (TBW − IBW)

Janmahasatian S, et al. Clin Pharmacokinet. 2005;44(10):1051–1065. doi:10.2165/00003088-200544100-00004 ·  Cockcroft DW, Gault MH. Nephron. 1976;16(1):31–41. PubMed

Evidence for Colin 2019 in obesity

External evaluation in 49 obese adults (15 with BMI of 40 or more). Colin 2019 had the lowest a-priori imprecision and the best a-posteriori bias and imprecision among the models compared; the cohort is small.

Colin PJ, et al. Ther Drug Monit. 2021;43(1):126-130. PMID: 33278242. PubMed

7. Adjusting estimates with blood levels

Vancomyzer uses Bayesian estimation to combine the population model with the patient’s measured blood levels. It considers both the agreement with those levels and how far the estimates differ from the population starting values. It compares several possible solutions to reduce the chance of settling on a poorer fit. The method is called maximum a posteriori (MAP) estimation; the equation and assumptions are shown below.

minimize  Σᵢ ½·((Cᵢ_obs − Cᵢ_pred) / σᵢ)² + ln(σᵢ)
        + ½·(ln(CL/CL_prior) / ω_CL)²
        + ½·(ln(V1/V1_prior) / ω_V1)²
        + ½·(ln(Q /Q_prior ) / ω_Q )²
        + ½·(ln(V2/V2_prior) / ω_V2)²

Assay error model:
  σᵢ = max(1.0 mg/L, 0.15 × max(Cᵢ_obs, Cᵢ_pred))

Bounds: each fitted parameter is limited to between one-tenth and ten times its prior value.

Prior log-SDs (Vancomyzer settings, all adults):
  ω_CL = 0.35    ω_V1 = 0.25    ω_Q = 0.50    ω_V2 = 0.50

With MAP estimation, a single observation is weighed against the prior rather than replacing it. The prior widths above are Vancomyzer settings, not the published Colin 2019 variability shown in section 1. When the residual exceeds 25% relative error, the calculator displays a Fit Quality Advisory and recommends a confirmatory level rather than overriding the prior.

The 90% credible band on the graph

The band shows uncertainty in the estimated concentrations. With blood levels available, the calculator considers 4,000 possible sets of pharmacokinetic values and selects 400 according to how well they agree with both the levels and the starting assumptions. Before levels are available, it uses 400 sets from the population assumptions. The middle 90% of the simulated concentrations forms the band at each time. The same inputs give the same band. Measurement error is excluded, so the band does not predict the range of a future blood test result. No band is shown when the estimate is unreliable or when the displayed parameters differ from the fitted values. The mathematical method is given below.

Proposal:   x ~ N(x̂_MAP, (1.5)² · H⁻¹)     x = ln(CL, V1, Q, V2), H = Hessian of the objective
Weight:     w ∝ exp(−objective(x)) / q(x)
Resample:   400 draws, systematic resampling
Band(t):    5th and 95th percentile of C(t) across the 400 draws

How often the band contains the true concentration in synthetic patients is reported on the software checks page. It has not yet been checked against measured patient levels.

8. AUC₂₄ target — ASHP/IDSA/PIDS/SIDP 2020

The therapeutic target of AUC₂₄ 400–600 mg·h/L (assuming MIC = 1 mg/L) follows the 2020 revised consensus guideline for serious MRSA infections. The guideline no longer recommends trough-only monitoring and recommends AUC-guided dosing, preferably with Bayesian estimation, citing data associating AUC-guided dosing with less acute kidney injury than trough-guided dosing. The calculator’s recommendation search picks the dose × interval combination whose predicted steady-state AUC sits closest to the midpoint of this range.

Rybak MJ et al. Am J Health Syst Pharm. 2020;77(11):835–864. doi:10.1093/ajhp/zxaa036

Foundational texts

  • Rowland M, Tozer TN. Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications. 4th ed. Lippincott Williams & Wilkins; 2011.
  • Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. Marcel Dekker; 1982.

Decision support, not a substitute for judgment

These models, equations and references are published for transparency and audit. Vancomyzer™ is designed to meet the criteria for non-device clinical decision support in section 520(o)(1)(E) of the Federal Food, Drug, and Cosmetic Act (added by section 3060 of the 21st Century Cures Act). It has not been cleared, approved or otherwise reviewed by the FDA. It is intended for licensed healthcare professionals, who must independently review the basis for each recommendation. Vancomyzer has not yet been validated in real patients. Its equations are checked against published values and synthetic test cases; external validation with patient data is planned. See the full Medical Disclaimer.